Positive News SentimentPositive NewsNASDAQ:SOPH SOPHiA GENETICS (SOPH) Stock Price, News & Analysis $3.11 -0.06 (-2.02%) As of 09:35 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About SOPHiA GENETICS Stock (NASDAQ:SOPH) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get SOPHiA GENETICS alerts:Sign Up Key Stats Today's Range$3.02▼$3.0250-Day Range$3.00▼$4.8852-Week Range$2.70▼$6.28Volume110 shsAverage Volume68,313 shsMarket Capitalization$207.73 millionP/E RatioN/ADividend YieldN/APrice Target$6.80Consensus RatingModerate Buy Company OverviewSOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific. SOPHiA GENETICS SA was incorporated in 2011 and is headquartered in Rolle, Switzerland.Read More… Remove Ads SOPHiA GENETICS Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks58th Percentile Overall ScoreSOPH MarketRank™: SOPHiA GENETICS scored higher than 58% of companies evaluated by MarketBeat, and ranked 414th out of 930 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingModerate Buy Consensus RatingSOPHiA GENETICS has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageSOPHiA GENETICS has received no research coverage in the past 90 days.Read more about SOPHiA GENETICS's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for SOPHiA GENETICS are expected to grow in the coming year, from ($0.96) to ($0.81) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of SOPHiA GENETICS is -2.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of SOPHiA GENETICS is -2.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about SOPHiA GENETICS's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.09% of the float of SOPHiA GENETICS has been sold short.Short Interest Ratio / Days to CoverSOPHiA GENETICS has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in SOPHiA GENETICS has recently decreased by 21.52%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSOPHiA GENETICS does not currently pay a dividend.Dividend GrowthSOPHiA GENETICS does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.09% of the float of SOPHiA GENETICS has been sold short.Short Interest Ratio / Days to CoverSOPHiA GENETICS has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in SOPHiA GENETICS has recently decreased by 21.52%, indicating that investor sentiment is improving significantly. News and Social Media3.7 / 5News Sentiment1.61 News SentimentSOPHiA GENETICS has a news sentiment score of 1.61. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.74 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for SOPHiA GENETICS this week, compared to 2 articles on an average week.Search Interest1 people have searched for SOPH on MarketBeat in the last 30 days. MarketBeat Follows1 people have added SOPHiA GENETICS to their MarketBeat watchlist in the last 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, SOPHiA GENETICS insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.88% of the stock of SOPHiA GENETICS is held by insiders.Percentage Held by InstitutionsOnly 31.59% of the stock of SOPHiA GENETICS is held by institutions.Read more about SOPHiA GENETICS's insider trading history. Receive SOPH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for SOPHiA GENETICS and its competitors with MarketBeat's FREE daily newsletter. Email Address SOPH Stock News HeadlinesMorgan Stanley Keeps Their Hold Rating on SOPHiA GENETICS (SOPH)March 20, 2025 | markets.businessinsider.comSOPHiA GENETICS (SOPH) Gets a Buy from BTIGMarch 18, 2025 | markets.businessinsider.comTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.April 2, 2025 | Porter & Company (Ad)SOPHiA GENETICS Announces Two Million Patient Cases Analyzed, Marking a New Milestone for Data-Driven Medicine at NVIDIA GTCMarch 18, 2025 | prnewswire.comSOPHiA GENETICS (SOPH) Receives a Buy from BTIGMarch 12, 2025 | markets.businessinsider.comBaby Sophia from embryo swap will stay with birth parents court rules on appealMarch 11, 2025 | msn.comDistrict Court rules to keep IVF child with birth mother following embryo mix-upMarch 10, 2025 | msn.comCourt overturns ruling that ordered toddler returned to genetic parents following embryo mix-upMarch 10, 2025 | msn.comSee More Headlines SOPH Stock Analysis - Frequently Asked Questions How have SOPH shares performed this year? SOPHiA GENETICS's stock was trading at $3.07 at the beginning of 2025. Since then, SOPH stock has increased by 3.3% and is now trading at $3.17. View the best growth stocks for 2025 here. How were SOPHiA GENETICS's earnings last quarter? SOPHiA GENETICS SA (NASDAQ:SOPH) announced its quarterly earnings results on Tuesday, March, 4th. The company reported ($0.23) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.23). The business had revenue of $17.73 million for the quarter, compared to analyst estimates of $17.71 million. SOPHiA GENETICS had a negative net margin of 110.71% and a negative trailing twelve-month return on equity of 55.06%. When did SOPHiA GENETICS IPO? SOPHiA GENETICS (SOPH) raised $234 million in an initial public offering (IPO) on Friday, July 23rd 2021. The company issued 13,000,000 shares at a price of $17.00-$19.00 per share. How do I buy shares of SOPHiA GENETICS? Shares of SOPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of SOPHiA GENETICS own? Based on aggregate information from My MarketBeat watchlists, some other companies that SOPHiA GENETICS investors own include Occidental Petroleum (OXY), PayPal (PYPL), Chesapeake Energy (CHK), Cheniere Energy (LNG), Rocket Pharmaceuticals (RCKT), AbCellera Biologics (ABCL) and Farmers & Merchants Bancorp (FMAO). Company Calendar Last Earnings3/04/2025Today4/02/2025Next Earnings (Estimated)5/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:SOPH CIK1840706 Webwww.sophiagenetics.com Phone41-21-694-1060FaxN/AEmployees520Year FoundedN/APrice Target and Rating Average Stock Price Target$6.80 High Stock Price Target$11.00 Low Stock Price Target$5.00 Potential Upside/Downside+114.5%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($0.95) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-78,980,000.00 Net Margins-110.71% Pretax Margin-109.76% Return on Equity-55.06% Return on Assets-38.33% Debt Debt-to-Equity Ratio0.12 Current Ratio3.80 Quick Ratio3.59 Sales & Book Value Annual Sales$65.17 million Price / Sales3.24 Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares66,687,000Free Float62,185,000Market Cap$211.40 million OptionableNot Optionable Beta1.01 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free Report This page (NASDAQ:SOPH) was last updated on 4/2/2025 by MarketBeat.com Staff From Our PartnersDOGE could send 6 AI stocks through the roofStay alert for Elon Musk and the Department of Government Efficiency's next move … Expect an announcement f...Weiss Ratings | SponsoredTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredMost gold “analysts” aren’t really gold analysts… [watch out]People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | Sponsored10X Bigger than AI, quantum, EVs, crypto, and robotics combined?World Economic Forum: "Arguably the Most Exciting Human Discovery Since Fire" Sam Altman, Bill Gates, and M...Stansberry Research | SponsoredTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SOPHiA GENETICS SA Please log in to your account or sign up in order to add this asset to your watchlist. Share SOPHiA GENETICS With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.